Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2020-11-11 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document explicitly starts with 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' multiple times. The content describes a 'Price Monitoring Extension' for a security, which is a specific type of market announcement related to trading mechanisms. This type of general, time-sensitive regulatory announcement that doesn't fit into the specific categories like 10-K, ER, or DIV is best classified under the general regulatory announcement category, RNS.
2020-11-11 English
Comment on the COVID-19 vaccine announcement
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 8922E' and concludes with information about RNS, the news service of the London Stock Exchange, stating it is approved by the Financial Conduct Authority (FCA) to act as a Primary Information Provider. This strongly indicates a regulatory announcement disseminated via the RNS system. The content itself is a brief comment on external news (Pfizer vaccine) and an update on the company's own clinical trial progress (SFX-01 for ARDS). Since it is a short, timely announcement of operational/clinical progress distributed through the official regulatory news service, and it doesn't fit the specific definitions for ER (Earnings Release), IR (Interim Report), or CAP (Financing Update), the most appropriate general category for a miscellaneous regulatory announcement distributed via RNS is 'Regulatory Filings' (RNS). It is not a Report Publication Announcement (RPA) because it is the substantive update itself, not just an announcement *about* a report.
2020-11-11 English
Launch of Nuvec® Oncology Treatment Programme
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 5684E' and contains standard regulatory boilerplate language, including references to 'National Storage Mechanism' and 'RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' The content announces a specific business development: the launch of an 'Oncology Treatment Programme' with Nanomerics and mentions that the information constitutes 'inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.' This is a general, time-sensitive regulatory announcement that does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or shareholder votes (DVA). Therefore, it falls best under the general Regulatory Filings category (RNS). The document length (4762 chars) is short, but it is the primary announcement itself, not an announcement *about* another report, so RPA is less appropriate than RNS for this type of corporate update.
2020-11-09 English
Verona Pharma Announces November 2020 Virtual Investor Conference Participation
Report Publication Announcement Classification · 1% confidence The document is a press release from Verona Pharma announcing that its CEO will present an overview at two upcoming virtual investor conferences in November 2020. It provides the dates, times, and webcast details for these presentations. This type of announcement, detailing executive participation in investor events, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or an announcement about future presentations. Since the document is short (4202 chars) and serves primarily to inform investors about where management will be speaking, it aligns best with the general category of investor communications. However, none of the definitions perfectly capture an announcement of *future* presentations. The closest fit among the specific codes is 'Investor Presentation' (IP), but given the nature of the text (announcing participation rather than attaching the presentation material), and the fact that it is a general corporate announcement about investor relations activities, it could also be considered a Regulatory Filing (RNS) if it doesn't fit elsewhere. Given the content is explicitly about management presenting company information to investors, 'Investor Presentation' (IP) is the most contextually relevant classification, even though it's an announcement *about* presentations, as it directly relates to investor outreach materials. Revisiting the definitions: IP is 'Detailed presentation for investors focusing on financials, strategy, and market position.' This document announces where such presentations will occur. If the document were the actual presentation slides or a detailed report, IP would be correct. Since it is a brief announcement about future events, it functions as a general corporate update. Given the options, and recognizing this is a standard investor relations update, I will classify it as an Investor Presentation (IP) as it pertains directly to investor engagement events, or potentially RNS as a general announcement. Since the content is highly focused on investor events, IP is stronger than the general fallback RNS.
2020-11-09 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields detailing the 'Identity of the issuer', 'Reason for the notification' (acquisition/disposal of voting rights/financial instruments), 'Details of person subject to the notification obligation' (SPREADEX LTD), and 'Total positions of person(s) subject to the notification obligation' showing percentage changes in voting rights (e.g., 2.20% direct, 2.03% indirect). This structure is characteristic of regulatory filings concerning changes in significant share ownership thresholds. This directly matches the definition for Major Shareholding Notification (MRQ).
2020-11-06 English
Operational Update
Management Reports Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange.' The content is an 'Operational Update' detailing ongoing research (Optimisation, Covid-19 Proof of Concept, Oral Application) and includes commentary from the CEO. This format—a brief, timely update on company operations and progress, often containing 'inside information' and distributed via the RNS system—is characteristic of a general regulatory announcement that doesn't fit the specific definitions of 10-K, ER, or IR. Since it is a regulatory announcement distributed via RNS and doesn't fit a more specific category like DIV, DIRS, or ER, the most appropriate fallback category is Regulatory Filings (RNS). The document length (6476 chars) is substantial enough that it is the report itself, not just an announcement of a report (RPA).
2020-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.